A First in Human (FIH) Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DR10624

PHASE1CompletedINTERVENTIONAL

Enrollment

153

Participants

Timeline

Start Date

June 22, 2022

Primary Completion Date

October 10, 2024

Study Completion Date

January 31, 2025

Conditions

Healthy, Obesity, Metabolically

Interventions

DRUG

DR10624 for injection

administered via subcutaneous injection

DRUG

Placebo

administered via subcutaneous injection

Trial Locations (1)

New Zealand Clinical Research, Christchurch

All Listed Sponsors

lead

Zhejiang Doer Biologics Co., Ltd.

INDUSTRY